Navigating the red: Diagnostic dilemma of erythema and diffuse body rash post- intrathecal baclofen pump implantation
Intrathecal drug delivery system (IDDS) infections can be localized to the pump pocket site and/or the catheter insertion site or become systemic, all potentially resulting in IDDS explant. Given the well-established effectiveness of IDDS for chronic non-cancer pain, cancer-associated pain, and spasticity, clinicians must differentiate between localized and systemic post-operative IDDS infections, as well as identify other causes of post-surgical skin irritation while avoiding unnecessary device explanation and therapy interruption. In this letter-to-the-editor, we describe and discuss the importance of taking a thorough patient history and utilizing both critical clinical decision-making as well as expertise from other subspecialists to care for IDDS patients and navigate problematic skin reactions following implant.
Authors
- J. Roger Hollister
- Chelsey M. Hoffmann (ORCID: https://orcid.org/0000-0002-2706-0279)
- William D. Mauck (ORCID: https://orcid.org/0000-0003-0704-181X)
- Oludare O. Olatoye (ORCID: https://orcid.org/0000-0003-2923-7290)
- Annie Bell Howrigon
Institutions
- Mayo Clinic in Arizona (US)
Publication Details
- Journal
- Interventional Pain Medicine
- Published
- 2025-04-15
- DOI
- https://doi.org/10.1016/j.inpm.2025.100584
- Primary Topic
- Botulinum Toxin and Related Neurological Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00